Tokio Marine Asset Management Co. Ltd. Increases Position in Eli Lilly and Company (LLY)
Tokio Marine Asset Management Co. Ltd. boosted its stake in Eli Lilly and Company (NYSE:LLY) by 8.8% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 69,285 shares of the company’s stock after buying an additional 5,633 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in Eli Lilly and were worth $5,927,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds also recently made changes to their positions in LLY. Acrospire Investment Management LLC boosted its holdings in Eli Lilly and by 16.7% in the 2nd quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock valued at $115,000 after purchasing an additional 200 shares during the period. MPS Loria Financial Planners LLC bought a new stake in Eli Lilly and in the 2nd quarter valued at about $128,000. San Francisco Sentry Investment Group CA bought a new stake in Eli Lilly and in the 2nd quarter valued at about $129,000. Point72 Asia Hong Kong Ltd boosted its holdings in Eli Lilly and by 237.4% in the 1st quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock valued at $148,000 after purchasing an additional 1,239 shares during the period. Finally, Shine Investment Advisory Services Inc. bought a new stake in Eli Lilly and in the 2nd quarter valued at about $148,000. Institutional investors and hedge funds own 76.43% of the company’s stock.
A number of analysts have issued reports on the stock. BMO Capital Markets set a $73.00 price objective on shares of Eli Lilly and and gave the company a “sell” rating in a report on Tuesday, October 24th. Barclays boosted their price objective on shares of Eli Lilly and from $90.00 to $98.00 and gave the company an “overweight” rating in a report on Friday, October 13th. Berenberg Bank reissued a “buy” rating and issued a $98.00 price objective on shares of Eli Lilly and in a report on Thursday, October 26th. Zacks Investment Research downgraded shares of Eli Lilly and from a “buy” rating to a “hold” rating in a report on Monday, October 30th. Finally, Cowen reissued a “buy” rating and issued a $95.00 price objective on shares of Eli Lilly and in a report on Wednesday, October 4th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and nine have given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $90.25.
Shares of Eli Lilly and Company (NYSE:LLY) opened at $86.45 on Friday. Eli Lilly and Company has a twelve month low of $67.22 and a twelve month high of $89.09. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66. The firm has a market cap of $95,189.66, a P/E ratio of 21.14, a PEG ratio of 1.90 and a beta of 0.35.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.02. The company had revenue of $5.66 billion during the quarter, compared to the consensus estimate of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The firm’s quarterly revenue was up 9.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.88 EPS. research analysts forecast that Eli Lilly and Company will post 4.21 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, December 8th. Investors of record on Wednesday, November 15th were paid a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.41%. The ex-dividend date was Tuesday, November 14th. Eli Lilly and’s payout ratio is 98.58%.
In related news, major shareholder Lilly Endowment Inc sold 195,000 shares of the stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $85.14, for a total value of $16,602,300.00. Following the completion of the transaction, the insider now owns 123,513,247 shares of the company’s stock, valued at approximately $10,515,917,849.58. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Alfonso G. Zulueta sold 2,003 shares of the stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $83.67, for a total transaction of $167,591.01. Following the completion of the transaction, the senior vice president now directly owns 43,580 shares of the company’s stock, valued at approximately $3,646,338.60. The disclosure for this sale can be found here. In the last three months, insiders sold 628,588 shares of company stock valued at $53,399,536. 0.20% of the stock is owned by insiders.
COPYRIGHT VIOLATION WARNING: This article was first published by Watch List News and is owned by of Watch List News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://www.watchlistnews.com/tokio-marine-asset-management-co-ltd-increases-position-in-eli-lilly-and-company-lly/1755717.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.